Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,688

Progress with Alzheimers and this time approaching it from the direction of Tau as a target rather than Beta Amyloid. This therapy has been tested in people and whilst it is only the first step hopefully this will lead to an effective treatment for this horrific diseases and and end to the suffering it brings.

Progress towards immunotherapies that can clear tau for Alzheimers here. Most therapies are focused on misfolded amyloid-β proteins but this particular approach targets Tau and the first in human test has proceeded!

“The authors of the study have developed a vaccine that stimulates the production of an antibody that specifically targets pathological tau, discovering its “Achilles’ heel”. It is able to do this because healthy tau undergoes a series of changes to its structure forming a new region that the antibody attacks. This new region (the “Achilles’ heel”), while not present in healthy tau, is present in diseased tau early on. Therefore, the antibody tackles all the different varieties of pathological tau. In addition to this important specificity, the antibody is coupled to a carrier molecule that generates a considerable immune response with the added benefit that it is not present in humans, thus avoiding the development of an immune reaction towards the body itself.”

#aging #crowdfundthecure

Read more

Tiny machines like nanorockets are ideal candidates for drug delivery in the human body. Chemists at Radboud University now demonstrate the first complete movement regulation of a nanorocket, by providing temperature responsive brakes. An interesting feature for practical applications, since temperature sensitivity enables the rocket to stop in diseased tissues where temperatures are higher. Nature Chemistry publishes their results on December 12.

The soft nanosystems that the bio-organic chemists at Radboud University work with self assemble, which means that they spontaneously form functional units. This allows the nanorockets to change shape, making them ideal candidates for containing cargo like medicine. ‘Our biggest challenge is to provide our nanorockets with various functionalities’, says Daniela Wilson, head of Radboud University’s Bio-organic chemistry department and Nanomedicine theme leader ‘We now demonstrate the first molecularly built brake system, enabling the rockets to start and stop at desired locations.’

Read more

After getting off its $100 million-plus IPO in the summer, gene editing biotech Intellia Therapeutics is getting ready for human tests of its preclinical CRISPR tech with new digs designed to help bolster its research capabilities.

The biotech, which has the backing and partnerships of the likes of Atlas, Novartis and Regeneron, is on the move as it heads over to its new lab facilities at 40 Erie Street, in Cambridge, MA.

“The field of genome editing is rapidly evolving and our work to develop therapies for patients requires that we have the infrastructure necessary for R&D growth and prepare for preclinical studies and clinical trials,” said Dr. Nessan Bermingham, CEO and founder of Intellia Therapeutics.

Read more

Removing Glucosepane crosslinks from tissue is one of the most important things groups like SENS Research Foundation are doing and their progress relies on our support.

In this interesting open access paper, the authors propose that too little attention has been given to immune cell behavior in tissues rather than in blood, and that means that researchers have overlooked the possibility that age-related changes in the extracellular matrix structures that support tissues might be a significant cause of the growing immune dysfunction that takes place in later life. One of the more important of these changes in the extracellular matrix is the growing presence of cross-links, persistent sugary compounds produced as a byproduct of normal metabolic operations that chain together the large molecules of the extracellular matrix. In doing so these cross-links change the chemical and structural properties of the matrix and the tissue as a whole, producing results such as loss of elasticity in skin and blood vessels, which in turn contribute to a variety of age-related diseases. If cross-linking does indeed contribute to immunosenescence, the decline of the immune system with age, then that only increases the importance of ongoing research funded by the SENS Research Foundation aimed at safely breaking down this unwanted form of metabolic waste. In humans near all persistent cross-links appear to involve a single class of compound, glucosepane. So in theory there is only a single target here, needing just one drug development program to make a large difference to long-term health and longevity.

Read more

This is one of the Nextbigfuture article series reviewing developments in 2016 and looking ahead to developments over the next few years. Here we look at 2016 in space. Later articles will look at medicine, life extension, energy and other areas. Previously we reviewed computers and artificial intelligence

The biggest developments in space in 2016.

SpaceX had several successful launches and landed several rocket stages but had an accident which has grounded SpaceX. They hope to launching again in January 2017.

Read more

Researchers at University of California, Santa Barbara, have designed a functional nanoscale computing element that could be packed into a space no bigger than 50 nanometres on any side.

red blood cell nanotechnology nanotech future timeline

In 1959, renowned physicist Richard Feynman, in his talk “Plenty of Room at the Bottom” spoke of a future in which tiny machines could perform huge feats. Like many forward-looking concepts, his molecule and atom-sized world remained for years in the realm of science fiction. And then, scientists and other creative thinkers began to realise Feynman’s nanotechnological visions.

Read more

You have the power to change the future of medicine and how we treat age-related diseases. Here is an example of how grassroots fundraising is changing science.

Joining the circulatory system of an old with a young animal has been shown to rejuvenate old tissues. Here the authors describe a comparatively simple blood infusion system that allows for the controlled exchange of blood between two animals, and study the effects of a single exchange on various tissues.

Read more

The CellAge AMA is open for questions, come along and ask about biotechnology, senolytics and so on.

Welcome to the CellAge AMA with Mantas Matjusaitis, PhD student in synthetic biology and founder of CellAge. I am here to talk about our work to improve the targeting of dysfunctional “senescent” cells in the body, and thereby aid in their eventual removal. This is important because removal of these cells has been shown to be a critical component in the effort to improve healthy human lifespan.

In short, CellAge is going to develop synthetic DNA promoters which are specific to senescent cells, as the promoters that are currently used for this purpose, such as the p16 gene promoter, suffer from various issues and limitations (not comprehensively targeting all senescent cells, collateral damage in targeting some cells that are not senescent, etc.). You can find more details in our technology video here, and on our Lifespan.io information page.

Seeing as our primary mission is to expand the interface between synthetic biology and aging research, as well as drive translational research forward, we will offer the senescence reporter assay we develop to academics for free. We predict that in the very near future this assay will be also used as a quality control step in the cell therapy manufacturing process to make cell therapies safer.

Read more

In Brief

  • Facebook billionaire Mark Zuckerberg recently opened his wallet in order to create BioHub, a $600 million center that will focus on working to create a human cell directory.
  • By mapping the trillions of cells in the human body, experts would be able to develop new drugs and vaccines to combat — and potentially end — disease.

Last month, we reported on the Human Cell Atlas, a project that plans to provide a detailed reference map of the human body’s trillions of cells. Yes, trillions. Once completed, the project could revolutionize healthcare by giving doctors and researchers a better way to predict, diagnose, and treat diseases.

Initiatives like this need funding – so Facebook billionaire Mark Zuckerberg opened his wallet and founded BioHub, a $600 million center that will focus on helping create a human cell directory. Zuckerberg and his wife, Priscilla Chan, plan to give away $3 billion over 10 years to fight disease, and BioHub is the couple’s first initiative.

Read more